Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer

Molecular Medicine Reports

Volumn 5, Issue 4, 2012, Pages 901-904

  Jeong, Tae O ^a   Oh, Kyung Jin ^a   Nguyen, Nguyen Thi Xuan ^a   Kim, Young Rang ^a   Kim, Min Soo ^b   Lee, Sang Don ^c   Ryu, Soo Bang ^a   Jung, Chaeyong ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

Author keywords

Cancer recurrence; Diagnostic marker; HOX; HOXB13; Prostate cancer

Indexed keywords

HOMEODOMAIN PROTEIN; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN HOX B13; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENT CANCER;

AGED; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863291665     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.769     Document Type: Article

References (23)

1. Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2: 777-785, 2002.
2. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al: Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13: 966-977, 1999. (Pubitemid 29200980)
3. Bowen C, Bubendorf L, Voeller HJ, et al: Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60: 6111-6115, 2000.
4. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al: Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62: 2999-3004, 2002. (Pubitemid 34602384)
5. Feber A, Clark J, Goodwin G, et al: Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23: 1627-1630, 2004. (Pubitemid 38406526)
6. Hood L, Heath JR, Phelps ME and Lin B: Systems biology and new technologies enable predictive and preventative medicine. Science 306: 640-643, 2004. (Pubitemid 39440903)
7. Sreenath T, Orosz A, Fujita K and Bieberich CJ: Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 41: 203-207, 1999. (Pubitemid 29508615)
8. Takahashi Y, Hamada J, Murakawa K, et al: Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res 293: 144-153, 2004. (Pubitemid 38064421)
9. Economides KD and Capecchi MR: Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130: 2061-2069, 2003. (Pubitemid 36656703)
10. Jung C, Kim RS, Zhang HJ, Lee SJ and Jeng MH: HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64: 9185-9192, 2004. (Pubitemid 39665535)
11. Kim YR, Oh KJ, Park RY, et al: HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer 9: 124, 2010
12. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004. (Pubitemid 38748922)
13. Komuves LG, Ma XK, Stelnicki E, Rozenfeld S, Oda Y and Largman C: HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development. Dev Dyn 227: 192-202, 2003. (Pubitemid 36666748)
14. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001. (Pubitemid 32801464)
15. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM and Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95: 661-668, 2003. (Pubitemid 36603722)
16. Rubin MA, Zhou M, Dhanasekaran SM, et al: alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670, 2002. (Pubitemid 34289218)
17. Foster CS, Falconer A, Dodson AR, et al: Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879, 2004. (Pubitemid 39093531)
18. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1451, 1997. (Pubitemid 27208886)
19. Zhao Y, Yamashita T and Ishikawa M: Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep 13: 721-726, 2005.
20. Edwards S, Campbell C, Flohr P, et al: Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 92: 376-381, 2005. (Pubitemid 40343155)
21. Reid JF, Lusa L, De Cecco L, et al: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97: 927-930, 2005. (Pubitemid 41417944)
22. Okuda H, Toyota M, Ishida W, et al: Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25: 1733-1742, 2006.
23. Economides KD, Zeltser L and Capecchi MR: Hoxb13 mutations cause overgrowth of caudal spinal cordand tail vertebrae. Dev Biol 256: 317-330, 2003. (Pubitemid 36390101)